Corey A. Carter
Advanced in Thymic Epithelial Tumor

Dr. Corey A. Carter

Hematology Oncology
8901 Wisconsin Ave, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Thymic Epithelial Tumor
8901 Wisconsin Ave, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Corey Carter is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Carter is rated as an Advanced provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor.

His clinical research consists of co-authoring 76 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Thymic Epithelial Tumor.

Specialties
Hematology Oncology
Licenses
Internal Medicine in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

8901 Wisconsin Ave, Bethesda, MD 20889

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
Enrollment Status: Completed
Publish Date: November 18, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

76 Total Publications

Correlation of safety and efficacy of atezolizumab therapy across indications.
Correlation of safety and efficacy of atezolizumab therapy across indications.
Journal: Journal for immunotherapy of cancer
Published: October 18, 2024
Similar Doctors
Distinguished in Thymic Epithelial Tumor
Dr. Taofeek K. Owonikoko
Hematology Oncology | Hematology | Oncology
Distinguished in Thymic Epithelial Tumor
Dr. Taofeek K. Owonikoko
Hematology Oncology | Hematology | Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (32.2 miles away)
410-328-1230
Languages Spoken:
English, German, Spanish, Yoruba
See accepted insurances
Accepting New Patients

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as an Elite provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Distinguished in Thymic Epithelial Tumor
Dr. Christine L. Hann
Hematology Oncology | Oncology
Distinguished in Thymic Epithelial Tumor
Dr. Christine L. Hann
Hematology Oncology | Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (33.9 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christine Hann is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Thymic Epithelial Tumor. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Hann is currently accepting new patients.

Advanced in Thymic Epithelial Tumor
Dr. James L. Gulley
Hematology Oncology
Advanced in Thymic Epithelial Tumor
Dr. James L. Gulley
Hematology Oncology
10 Center Dr., 8b08, Msc 1750, 
Bethesda, MD 
 (0.6 miles away)
301-435-2956
Languages Spoken:
English

James Gulley is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Gulley is rated as a Distinguished provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Prostate Cancer, Olfactory Neuroblastoma, Chordoma, Urothelial Cancer, and Orchiectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carter's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile